Resof L (Generic Harvoni) Adelaide — Hepatitis C Cure South Australia 2026

 FAQ 1: How does South Australia's rural HCV burden — in the Riverland and wine regions — create access challenges that Resof L addresses?

South Australia's Riverland — stretching along the Murray River through Renmark, Berri, Loxton, and Waikerie — has a significant HCV burden linked to injection drug use patterns in rural and regional communities where healthcare access is limited to small rural hospitals and GP practices. HCV in the Riverland is managed primarily through: Berri and Renmark Hospital outreach clinics with visiting gastroenterologists from Royal Adelaide Hospital every 4-6 weeks; GP-initiated DAA prescribing (Australia's GP prescribing expansion has enabled Riverland GPs to prescribe Resof L without specialist referral — a major rural access improvement); and Hepatitis SA's community outreach workers who travel to Riverland communities for HCV testing and treatment support. The wine regions — Barossa Valley and McLaren Vale — contribute seasonal workers (Australian and international backpackers and agricultural workers) with HCV risk from prior injection drug use who may be diagnosed opportunistically during SA Health initiatives. Resof L from Unnati Pharmax serves Riverland and regional SA HCV patients who: have received a prescription through their rural GP but face delayed dispensing from rural pharmacy (some SA rural pharmacies don't stock Resof L without advance ordering); are international seasonal agricultural workers without Medicare who cannot access PBS-subsidised Resof L; or who for cost reasons prefer private supply during the administrative period between prescription and PBS approval confirmation.

 FAQ 2: What is Hepatitis SA's role in connecting Adelaide's HCV community with Resof L treatment?

Hepatitis SA — the peak South Australian community organisation for viral hepatitis — provides the navigation and support infrastructure that connects Adelaide's diverse HCV-affected communities with Resof L treatment. Hepatitis SA's programmes relevant to Resof L access: the SA Liver Clinic support programme — connecting newly diagnosed HCV-positive individuals from GP or hospital diagnosis directly to gastroenterology assessment and DAA prescribing with minimal waiting time; peer support workers — individuals with lived experience of HCV who provide non-judgmental, knowledgeable navigation through the treatment process; community outreach to prisons (Adelaide's Yatala Labour Prison and Adelaide Women's Prison have high HCV prevalence — Hepatitis SA advocates for and supports in-prison Resof L prescribing); and the SA HCV Point of Care Testing programme — using portable HCV testing equipment to bring HCV diagnosis to community settings including NSP outlets, homeless shelters, and youth services in Adelaide's northern suburbs. For Adelaide's HCV community members engaged with Hepatitis SA's services, Resof L from Unnati Pharmax complements the navigation support Hepatitis SA provides — offering an affordable private medication source for those who have been connected to prescribing through Hepatitis SA's work but face PBS access barriers due to Medicare eligibility or processing delays.

 FAQ 3: How does Resof L interact with medications commonly used for pain in Adelaide's older HCV population with liver disease?

Adelaide's HCV-positive population includes a significant proportion of older Australians — particularly those infected through unscreened blood transfusions before 1990 and those with long-term injection drug use histories — who now manage multiple chronic conditions including musculoskeletal pain. Safe pain management in HCV liver disease is an important clinical consideration for Resof L-treated patients. Paracetamol (acetaminophen): safe in HCV at standard doses (up to 2g daily in patients with cirrhosis, 4g daily in non-cirrhotic HCV) — the preferred analgesic for HCV patients. NSAIDs (ibuprofen, naproxen): caution in advanced fibrosis and cirrhosis due to impaired platelet function and risk of renal prostaglandin suppression in portal hypertension; avoided in decompensated cirrhosis. Tramadol: extended half-life in liver impairment; use with caution and reduced dosing in cirrhotic HCV patients on Resof L. Codeine: reduced hepatic activation to morphine in liver disease — less predictable analgesia in cirrhosis. Resof L-specific pain medication interactions: no pharmacokinetic interaction between Ledipasvir or Sofosbuvir and paracetamol, tramadol, or standard NSAIDs in patients with adequate liver function. The important interaction to avoid: amiodarone (occasionally used as an antiarrhythmic) is contraindicated with Sofosbuvir-containing Resof L due to severe bradycardia risk — Adelaide cardiologists treating HCV patients for cardiac arrhythmias must be aware of this critical combination.

 FAQ 4: How has Australia's GP prescribing expansion transformed HCV treatment access in Adelaide and what does it mean for Resof L uptake?

Australia's 2019 decision to expand Resof L and other PBS-listed DAA prescribing to all GPs — removing the requirement for specialist hepatologist or infectious disease physician involvement — was transformative for HCV elimination access in Adelaide and across Australia. Pre-2019, Adelaide's HCV treatment was gatekept through gastroenterology waitlists at Royal Adelaide and Flinders Medical Centre — wait times of 3-6 months meant many HCV-positive individuals who were motivated to treat couldn't access DAAs promptly. Post-2019 GP prescribing: an Adelaide GP who diagnoses HCV in a patient can prescribe Resof L (PBS authority required but straightforward) at the same appointment, initiating treatment within days of diagnosis — dramatically reducing the time from diagnosis to cure. Adelaide's GP network — including Aboriginal Community Controlled Health Organisations (ACCHOs) like Nunkuwarrin Yunti of SA Inc. and Pika Wiya Health Service in the Flinders Ranges — now prescribes Resof L for their Indigenous HCV-positive patients without requiring Adelaide specialist referral. This GP prescribing expansion has accelerated Adelaide's HCV elimination progress substantially. Resof L from Unnati Pharmax complements this expanded prescribing access — GPs who have prescribed Resof L can also advise patients on private supply pathways through Unnati Pharmax for those who cannot immediately access PBS supply.

 FAQ 5: What Aboriginal community-controlled HCV programmes in South Australia interface with Resof L treatment for Indigenous patients?

South Australia's Aboriginal and Torres Strait Islander population carries HCV rates approximately 7-10 times higher than non-Indigenous Australians — driven by injection drug use concentrated in specific communities and the structural determinants of colonisation. Adelaide's ACCHOs provide the culturally safe primary care context through which Indigenous SA patients most effectively engage with HCV diagnosis and Resof L treatment. Key SA Aboriginal health organisations involved in HCV: Nunkuwarrin Yunti of SA Inc. — Adelaide's largest ACCHO, providing comprehensive primary health care from multiple Adelaide sites including GP services that can now prescribe Resof L; Tullawon Health Service — serving the remote Anangu Pitjantjatjara Yankunytjatjara (APY) Lands in SA's far north; and Pika Wiya Health Service — serving Port Augusta and regional SA Aboriginal communities. Hepatitis SA's Aboriginal Community Worker programme embeds culturally informed HCV workers within these ACCHO services — speaking local Aboriginal languages and co-designing HCV testing and treatment engagement strategies with community Elders. SA Health's Aboriginal Health Division coordinates Resof L access through ACCHO pharmacies — many ACCHO sites now dispense Resof L directly after GP prescribing within the same service. This integrated, community-controlled model is the gold standard for reaching Indigenous SA HCV patients with Resof L treatment — Unnati Pharmax's role is complementary for urban Adelaide Indigenous patients navigating the intersection of ACCHO care and private supply needs.